X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427
https://endpts.com/an-allergan-psychiatric-drug-failed-late-stage-depression-studies-but-abbvie-is-going-for-approval-anyway/
https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/
https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/
https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-enhertu-s-big-win-biogen-samsung-s-lucentis-biosimilar-clover-s
https://www.fiercepharma.com/pharma/massive-tumor-progression-edge-astrazeneca-and-daiichi-s-enhertu-shows-roche-s-kadcyla-who-s
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427
https://www.chugai-pharm.co.jp/english/news/detail/20200821160000_758.html
http://www.pharmatimes.com/news/final_nhs_green_light_for_roches_kadcyla_1341980
http://www.pmlive.com/pharma_news/ema_backs_adjuvant_use_of_roches_breast_cancer_adc_kadcyla_1320584
https://www.centerforbiosimilars.com/news/as-biosimilars-emerge-in-oncology-and-rare-disease-innovator-companies-look-to-new-drugs-to-maintain-sales
https://www.businesswire.com/news/home/20191010005257/en/Seattle-Genetics-Announces-Initiation-Phase-3-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.fiercepharma.com/pharma/biosimilars-will-leave-a-10b-gap-roche-s-sales-but-new-drugs-can-more-than-fill-it-exec
https://www.thepharmaletter.com/in-brief/brief-chugai-seeks-new-kadcyla-indication-in-japan
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427
https://www.bloombergquint.com/business/roche-s-new-cancer-ms-drugs-pay-off-with-a-forecast-boost
https://www.fiercepharma.com/pharma/roche-s-stellar-hemlibra-ocrevus-results-q1-prompt-sunnier-2019-outlook
https://endpts.com/as-herceptin-biosimilars-eat-into-roche-sales-swiss-drugmaker-makes-case-for-expanded-kadcyla-use/?utm_medium=email&utm_campaign=657%20Tues%2020518%20Bispecific%20boom%20GSK%20leaps%20into%20head-to-head%20showdown%20with%20Keytruda%20Genentech%20bets%20big%20on%20an%20IL-15%20pipeline&utm_content=657%20Tues%2020518%20Bispecific%20boom%20GSK%20leaps%20into%20head-to-head%20showdown%20with%20Keytruda%20Genentech%20bets%20big%20on%20an%20IL-15%20pipeline+CID_a6d6804f2a96c48f05d1b0ac31eadcb7&utm_source=ENDPOINTS%20emails&utm_term=As%20Herceptin%20biosimilars%20eat%20into%20Roche%20sales%20Swiss%20drugmaker%20makes%20case%20for%20expanded%20Kadcyla%20use
https://www.fiercepharma.com/pharma/roche-nabs-coveted-fda-real-time-review-to-expand-kadcyla-to-early-breast-cancer-setting
https://www.reuters.com/article/us-roche-kadcyla/roche-moves-to-broaden-kadcyla-use-in-biosimilar-defense-idUSKCN1PU0ES
https://www.pharmacompass.com/pdf/news/roche-submits-sbla-to-fda-for-kadcyla-1549394765.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427
http://www.pharmatimes.com/news/roches_kadcyla_shows_promise_in_early_breast_cancer_1255837
https://www.chugai-pharm.co.jp/english/news/detail/20181012133002_555.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427
https://www.xconomy.com/boston/2018/09/17/fda-clears-mersana-to-restart-cancer-drug-test-with-new-safeguards/
http://www.moneycontrol.com/news/business/companies/odacs-approval-takes-us-one-step-closer-to-usfda-nod-for-trastuzumab-biocons-cmd-2325687.html
http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/breast-cancer-drug-kadcyla-to-be-routinely-available-in-wales/20203038.article
http://www.raps.org/Regulatory-Focus/News/2017/06/15/27920/NICE-Roche-Reach-Deal-on-Breast-Cancer-Drug/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails
http://www.pharmatimes.com/news/smc_u-turn_backs_roches_kadcyla_for_breast_cancer_1191182
http://www.nasdaq.com/article/roches-rhhby-lucentis-gets-fda-nod-for-fifth-indication-cm730635
http://www.pharmatimes.com/news/nice_backs_roches_perjeta,_but_bars_kadcyla_1183055
https://www.theguardian.com/society/2016/dec/29/breast-cancer-drug-kadcyla-rejected-for-nhs-use-on-cost-benefit-grounds
http://www.nasdaq.com/article/pfizer-pfe-nimenrix-vaccines-label-expanded-in-the-eu-cm724871
http://www.forbes.com/sites/greatspeculations/2016/12/06/roches-investors-remain-cautious-despite-improving-business/#4c2227de4858
http://www.fiercepharma.com/pharma/eisai-wins-nice-backing-for-older-halaven-but-still-isn-t-happy-about-lenvima
http://uk.reuters.com/article/us-roche-results-trial-idUKKCN12K1X2
http://www.bloomberg.com/news/articles/2016-04-19/roche-first-quarter-sales-gain-5-fueled-by-breast-cancer-trio
http://www.bloomberg.com/news/articles/2016-04-01/roche-sees-potential-for-u-k-to-lead-on-cancer-drug-payments
http://www.pmlive.com/news/sales/2016/january/roche_shares_slip_as_profits_miss_expectations_917938
http://www.bloomberg.com/news/articles/2016-01-28/roche-full-year-sales-beat-estimates-on-new-cancer-treatments?
http://www.bloomberg.com/news/articles/2016-01-22/bristol-myers-opdivo-gets-nod-for-melanoma-from-u-k-regulator
http://www.bloomberg.com/news/articles/2015-12-16/roche-discount-fails-to-win-breast-cancer-drug-backing-in-u-k-
http://www.pharmatimes.com/Article/15-12-16/NHS_patients_barred_from_BMS_Opdivo_Roche_s_Kadcyla.aspx?
http://www.fiercepharmamarketing.com/story/roche-challenges-hometown-rival-novartis-new-targeted-lung-cancer-med-alece/2015-12-14
http://www.fiercepharma.com/story/pfizers-ibrance-pricing-shows-multiyear-market-analysis-source-some-high-co/2015-12-09
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/swiss-drugmaker-roche-launches-costliest-cancer-drugs-in-india/articleshow/49927222.cms
Market Place
Share 
